For the Inventor, By the Inventor

Enter assignee name

Emeryville, CA, United States of America

Adamas Pharmaceuticals, Inc.

Calculating rank

USPTO Granted Patents = 29

% Expired Patents = 10.3

CIPO Patents = 6

EPO Patents = 6

Trademarks = 2

Forward Citations = 657

Loading Chart...

Loading Chart...

27 inventors (with patents filed for the assignee):

Gregory T Went (26 out of 40 patents)

Timothy J Fultz (25 out of 44 patents)

Laurence R Meyerson (19 out of 21 patents)

4. Seth Porter (10 out of 15 patents)

5. Timothy S Burkoth (10 out of 12 patents)

6. David Chernoff (4 out of 7 patents)

7. Jack Nguyen (4 out of 5 patents)

8. Glenn A Meyer (2 out of 36 patents)

9. Sangita Ghosh (2 out of 5 patents)

10. Ana Cristina Pastini (2 out of 8 patents)

11. Marcelo Fernando Befumo (2 out of 8 patents)

12. Mickey S Urdea (2 out of 5 patents)

13. Paul Spence (2 out of 2 patents)

14. Rowan Chapman (2 out of 2 patents)

15. Terry L Burkoth (2 out of 25 patents)

Core Competencies:

Neurological Disease

CNS Conditions

Seizure Disorders

NMDA Receptor Antagonist

Aminoadamantane Derivatives

Therapeutic Agents

Influenza Treatment

Composition Methods

29 patents: Sort by Forward Citations

1. 11890261 - Composition and method for treating neurological disease (2024-02-06),

2. 11833121 - Composition and method for treating neurological disease (2023-12-05),

3. 10987324 - Methods and compositions for the treatment of seizure-related disorders (2021-04-27),

4. 10973783 - Methods and compositions for the treatment of seizure-related disorders (2021-04-13),

5. 9072697 - Composition and method for treating neurological disease (2015-07-07),

6. 8987333 - Composition and method for treating neurological disease (2015-03-24),

7. 8895618 - Composition and method for treating neurological disease (2014-11-25),

8. 8895617 - Composition and method for treating neurological disease (2014-11-25),

9. 8895616 - Composition and method for treating neurological disease (2014-11-25),

10. 8895615 - Composition and method for treating neurological disease (2014-11-25),

11. 8895614 - Composition and method for treating neurological disease (2014-11-25),

12. 8889740 - Composition and method for treating neurological disease (2014-11-18),

13. 8741343 - Method of administering amantadine prior to a sleep period (2014-06-03),

14. 8580858 - Compositions for the treatment of CNS-related conditions (2013-11-12),

15. 8426472 - Method and composition for administering an NMDA receptor antagonist to a subject (2013-04-23),

Company Overview

Adamas Pharmaceuticals, Inc. is a biopharmaceutical company based in Emeryville, California, focused on developing innovative therapies for neurological diseases. The company specializes in creating treatments that address unmet medical needs, particularly in the areas of movement disorders and cognitive impairment. Through its research and development efforts, Adamas aims to improve the quality of life for patients suffering from conditions such as Parkinson's disease and other related disorders, leveraging advanced drug formulation technologies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

29 Patents

#20 in Emeryville, CA

#2,768 in California

#11,634 in US

#22,581 in the World

Emeryville, CA, United States of America

Adamas Pharmaceuticals, Inc.

Forward Citations = 657

27 inventors:

Gregory T Went (26 out of 40 patents)

Timothy J Fultz (25 out of 44 patents)

Laurence R Meyerson (19 out of 21 patents)

4. Seth Porter (10 out of 15 patents)

5. Timothy S Burkoth (10 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Adamas Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/adamas-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…